Page 5 - Pharma Sector

IT, pharma, textile, auto ancillary sectors stand to gain from a weak rupee

The textiles sector saw a recovery in Q4FY21 and a weaker rupee could make it more competitive, and boost exports

Mankind Pharma inks distribution pact with BDR Pharma for Covid drug

Delhi-based Mankind Pharma operates in 34 overseas destinations.

GSK's drugs arm to get $11 billion windfall from consumer spin-off

Investors have been waiting for details of the separation

Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22

The company is looking to build new capacities and facilities that would propel its growth in the coming years

Laurus Labs trades higher for 8th straight day, soars 73% in 3 months

Shares of Laurus Labs continued their upward journey to hit a new high of Rs 599 on the BSE in intra-day trade on Tuesday

Sun Pharma, Ferring Pharma ink pact to introduce obstetric drug in India

The drug is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The medicines are a therapeutic equivalent of Banzel®

Divi's Labs gains 3%, hits new high on strong March quarter results

The board has recommended a dividend of Rs 20 (i.e. 1,000 per cent) per equity share of face value Rs 2 each for the financial year 2020-21

Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore

Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

PharmEasy acquires Medlife, becomes India's largest e-pharma company

As Medlife discontinues operations, its users will move seamlessly to Pharmeasy, which will now serve 2 million households every month

Health ministry panel vetting requests by six cos to make Mucormycosis drug

Development come amid fast spread of disease in various states and shortage of drugs to treat it; Rajasthan has already declared an epidemic

Pharma sector's Q4 results show moderate gains amid Covid-19 pandemic

The ongoing April-June quarter should see strong growth due to low base of last year

Covid second wave pushes India's pharma industry growth to 59% in April

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector

Returns from healthcare ETFs can be highly cyclical, say analysts

Avoid over 5% exposure and have 5-7 years of investment horizon

Cipla Q4 profit up 73% at Rs 412 cr, total revenue at Rs 4,606 cr

Drug major Cipla on Friday posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20. Total revenue from operations rose to Rs 4,606 crore as compared with Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing. For the entire 2020-21 fiscal year, the drug maker reported a consolidated net profit of Rs 2,389 crore as against Rs 1,500 crore in the previous year. Total revenue from operations for the last fiscal year rose to Rs 19,160 crore as against Rs 17,132 crore in 2019-20. The company's board recommended a final dividend of Rs 5 per share (face value Rs 2 each) for 2020-21. Cipla shares on Friday ended flat at Rs 904.10 apiece on the BSE.

This smallcap pharma stock has zoomed over 100% in a month

The stock of the smallcap pharmaceuticals company was trading at its 52-week high level on the BSE

FabiFlu numero uno in Indian pharma market, show April sales data

With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore

India's pharma market rebounds in April, clocks 51.5% sales growth

Low base of April 2020, pick-up in demand for Covid-19 drugs major contributors to growth

RBI's Covid relief: Good move, but late, says health care industry

While some companies said they were open to borrowing, others felt their working capital cycle was comfortable

Alembic Pharma falls 6% post March quarter results

Alembic Pharma Q4FY21 operational performance was marginally below estimates, largely due to lower traction in US and Domestic Formulation (DF) sales